Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00823797 · ClinicalTrials.gov registry record · Phase 2
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00823797 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 45 participants.
The verdict
NCT00823797, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This phase II trial studies how well bendamustine hydrochloride works in treating patients with anaplastic glioma or glioblastoma that has come back (recurrent) or growing, spreading or getting worse (progressive). Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Bendamustine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-10 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00823797
The ClinicalTrials.gov registry entry for NCT00823797 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT00823797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00823797 about?
NCT00823797 is a clinical study titled "Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma". This phase II trial studies how well bendamustine hydrochloride works in treating patients with anaplastic glioma or glioblastoma that has come back (recurrent) or growing, spreading or getting worse (progressive). Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different way...
What is the current status of trial NCT00823797?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2008-10. Estimated completion is 2017-04.
What interventions are being tested in trial NCT00823797?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Bendamustine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00823797?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.